BostonGene offers a powerful platform for integrated analysis of the patient and their tumor

BostonGene's AI-powered platform integrates molecular and immune profiling techniques to comprehensively analyze the tumor, microenvironment, and host immunity. Benefit from fast, accurate results in a CLIA-certified and CAP-accredited environment. Save time and resources with BostonGene's streamlined investigational process.
Mission

BostonGene’s mission is to power healthcare’s transition to personalized medicine using AI-based molecular and immune profiling to improve the standard of care, accelerate research, and improve economics.

Scientific publications

Scientific expertise and results of cutting-edge analysis by BostonGene are published in top scientific and clinical journals.

“Conserved pan-cancer microenvironment subtypes predict response to immunotherapy” is one of ten research articles that represent cutting-edge areas of cancer research and oncology in 2021 by Cancer Cell (Bagaev et al., 2021).

Why BostonGene?

BostonGene collaborates with leading cancer centers by providing innovative technologies to develop and validate novel precision medicine approaches.

“The University of Texas MD Anderson Cancer Center

“Through our collaboration with BostonGene, we will utilize multi-parameter discovery, big data analytics and computational support to advance and validate novel diagnostic and the-rapeutic biomarkers that we hope will guide physicians to deliver optimal care to each patient.”

Funda Meric-Bernstam, MD, Chair of Investigational Cancer Therapeutics, MD Anderson

Abramson Cancer Center of the University of Pennsylvania

“We look forward to using BostonGene’s technology to help in our work to better understand the mechanisms of cancer neoantigen recognition and to the discovery of new immunotherapy treat–ment options.”

Gerald Linette, MD, PhD, Clinical Director of the Parker Institute for Cancer Immunotherapy at UPenn

Massachusetts General Hospital Cancer Center

“The collaboration is a great expansion of our translational research portfolio. We hope this will enable new biomarker discovery and the identification of next generation precision medicines.”

David Ting, MD, Associate Clinical Director of Innovation, Mass General Cancer Center

For all questions please contact:
researchservices@bostongene.com
+1 781-552 -3131 (8:00am -5:00pm ET Monday–Friday).